A randomized trial of the efficacy and safety of azilsartan medoxomil combined with chlorthalidone
| Autor: | Attila Juhasz, Michael A. Weber, Andrew V. Roberts, Charlie Cao, Peter S. Sever |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Male
Medicine (General) medicine.medical_specialty Systole Urology Blood Pressure 030204 cardiovascular system & hematology law.invention 03 medical and health sciences R5-920 0302 clinical medicine Endocrinology Randomized controlled trial Diastole law Internal medicine Internal Medicine Humans Medicine 030212 general & internal medicine Azilsartan Medoxomil Oxadiazoles business.industry azilsartan medoxomil clinical trial 1103 Clinical Sciences Blood Pressure Monitoring Ambulatory Middle Aged 0606 Physiology angiotensin receptor blockers Clinical trial Treatment Outcome Cardiovascular System & Hematology Hypertension chlorthalidone Benzimidazoles Drug Therapy Combination Female Original Article Chlorthalidone Angiotensin Receptor Blockers Chlorthalidone 25 MG business medicine.drug |
| Zdroj: | Journal of the Renin-Angiotensin-Aldosterone System, Vol 19 (2018) Journal of the Renin-Angiotensin-Aldosterone System: JRAAS |
| ISSN: | 1752-8976 1470-3203 |
| Popis: | Introduction: We measured the effects of azilsartan medoxomil co-administered with chlorthalidone 25 mg in stage 2 hypertension. Methods: Azilsartan medoxomil 40 or 80 mg plus chlorthalidone were compared with placebo plus chlorthalidone once daily in a randomized, double-blind, 6-week trial. The primary endpoint was change from baseline in 24-hour mean systolic blood pressure by ambulatory blood pressure monitoring. Results: Patients ( N=551; mean age 59 years; 51.7% men) were randomly assigned to placebo plus chlorthalidone ( n=184), azilsartan medoxomil 40 mg plus chlorthalidone ( n=185), or azilsartan medoxomil 80 mg plus chlorthalidone ( n=182). Baseline systolic blood pressures were similar among groups. After 6 weeks, least squares mean (standard error) reductions with azilsartan medoxomil 40 mg and 80 mg plus chlorthalidone were similar in magnitude (−31.7 (1.0) and −31.3 (1.0) mmHg, respectively), but greater than chlorthalidone alone (−15.9 (1.0) mmHg). Hypotension and serum creatinine elevations were more frequent with azilsartan medoxomil plus chlorthalidone than chlorthalidone alone (reversed with drug discontinuation). Notably, plasma potassium reduction of 0.43 meq/L with chlorthalidone was attenuated to 0.13 and 0.05 meq/L by azilsartan medoxomil 40 mg and 80 mg, respectively. Conclusion: Azilsartan medoxomil 40 mg or 80 mg plus chlorthalidone 25 mg was significantly more efficacious than chlorthalidone alone in reducing blood pressure and was well tolerated. Clinicaltrial.gov , https://clinicaltrials.gov/ct2/show/NCT00591773 , NCT00591773 |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|